Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GSK US Pharma President Jack Bailey On A “Dynamic” 2017

Executive Summary

With new US President Trump in place, new corporate CEO Walmsley to take the reins in April and the opportunity for four US drug launches in 2017, GSK’s president of US Pharmaceuticals says he is preparing for an “intense” year.

Advertisement

Related Content

GSK Braces For Impact: Advair Generic Could Reduce US Brand To £1Bn
4Q Pharma Results Preview, Part 3: Gilead, GSK, Sanofi, Allergan, Shire, Bayer, Valeant
GSK Management Shake Up Ahead Of New CEO Sees Hussain Out, AZ's Miels In
Advair: A Big Generic Opportunity And A Big Question Mark In 2017
GSK Files Blockbuster Hopeful Shingrix With FDA
GSK's Immunology Strategy Edges Closer To Delivering
GSK Vaccines: Injecting Visibility

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register